According to Gate News bot, the latest announcement states that Gate will be delisting the trading markets for 16 tokens. The tokens involved in the delisting include JAM, ZP, MOJO, FLOAT, UROLITHINA, POP, DOSE, WIFI, GO, ORDS, LOOM, SKI, DRGN, STND, RLY, and PWAR along with their corresponding USDT trading pairs. Gate has suspended the deposit services for these tokens. The related trading services ( include spot trading, quantitative grid, idle coin treasure, and margin trading ) will be suspended on November 12, 2025, at 11:00 ( UTC+8. Gate will provide a repurchase service for users still holding these Tokens from November 26 to December 3, 2025, with a maximum compensation limit of 100 USDT per user.

ChainCatcher News, the new chairman of the SEC, Paul Atkins, stated that he intends to eliminate the mandatory quarterly reports for listed companies, allowing them to switch to semi-annual reports, and proposed a "minimum effective dose" regulatory principle, advocating for relaxed information disclosure requirements and supporting companies in deciding their reporting frequency based on market demands. This position is highly consistent with Trump's pro-business policies, representing a comprehensive shift of the SEC from strict regulation to "light-touch" regulation. Meanwhile, the SEC's attitude towards the regulation of Crypto Assets is also changing, shifting from previous high-pressure scrutiny to a more open acceptance, providing more possibilities for Compliance of digital assets. However, some investors are concerned that this move may weaken market transparency and affect the decision-making efficiency of retail investors. The SEC's reform may have a profound impact on the U.S. financial market and global compliance trends. The SEC will create favorable conditions for compliant fintech platforms including BiyaPay.

Gate News bot reported that Catriona Kellas, the Head of International Legal Projects at Franklin Templeton, stated at the DigiAssets 2025 conference that the EU could potentially become a "flyover zone" for Crypto Assets between the US and Asia due to the legislative pace lagging behind that of the US and Asia. "This technology does carry risks, and jurisdictions that may have been at the forefront a few years ago can easily fall behind if the legislative process takes too long," she said, noting that "other jurisdictions" have adopted more flexible policies in the Crypto Assets space. She indicated that the European Commission seems to have recognized this, recalling a recent conversation where "they mentioned a word I had never heard before, which is 'competition'." "They certainly asked the right questions," Kellas added, stating that the rumors surrounding "MiCA 2" (the updated version of the Markets in Crypto Assets regulation) are "far from rumors", with the legislation set to take effect in June 2023. "It may be coming soon," she added.

Jin10 data reported on June 12th that Hanyu Pharmaceutical stated on the interactive platform that the company's Semaglutide injection is being submitted for listing under Category 2. The weight loss indication completed the enrollment of all trial subjects for Phase III clinical trials in January this year and is currently in the follow-up phase, with the project having entered the dose maintenance period. After the completion of the future Phase III clinical trials, the company will organize and improve the clinical trial data according to relevant regulatory requirements and submit a listing application.

On February 5th, Jinshi Data reported that Novonordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. Last December, the data of this drug disappointed the market, leading to a 27% drop in the company's stock price, one of the largest single-day declines among European companies. Jorgensen, the CEO of the company, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they have seen in the data.

On August 15th, Jinshi Data reported that the Anhui Provincial Medical Centralized Procurement Platform announced the latest procurement catalog for the Anhui Province's 2024 coronavirus vaccine and some non-immunization plan vaccines. Watson Biotechnology's OmicronXBB.1.5, a new coronavirus variant bead mRNA vaccine, was included in the procurement catalog at a price of 278 yuan per dose. The previous day's price for this product was 94 yuan per dose, a decrease of about 70% compared to the price announced by Shandong. Watson Biotechnology confirmed that the price announced by Anhui on the previous day was incorrect, and the latest correct price is consistent with the price in Shandong, and there has been no price reduction.

The Anhui Provincial Medical Procurement Platform issued a notice to include the Watson Biological Omicron XBB.1.5 mRNA vaccine (variant bead) at a price of 94 yuan/dose in the procurement catalog, a decrease of 71.94% compared to the proposed listing price of 278 yuan/dose on the Shandong Provincial Public Resource Trading Platform.

On July 24th, Jinshi Data, Sage Therapeutics and Biogen announced the termination of the development of a proposed drug for the treatment of essential tremor of the nervous system, as the drug failed in a mid-term study. Sage and Biogen stated on Wednesday that a Phase II dose-ranging study showed no statistically significant differences in the change from baseline to day 91 in any dose of the investigational drug SAGE-324 compared to placebo. Sage Therapeutics' stock fell 28% pre-market.